Hidradenitis Suppurativa Market Size was valued USD 1.4 billion in 2023 and to grow rapidly by 2034

The Hidradenitis Suppurativa market size was valued at approximately USD 1.4 billion in 2023 and is projected to expand at a notable CAGR throughout the 2020–2034 forecast period. DelveInsight’s comprehensive market research provides critical insights into such market trends, enabling stakeholders to understand growth drivers, emerging opportunities, and potential challenges within the Oncolytic Virus Therapies landscape.

The United States held the largest share of the Hidradenitis Suppurativa market, valued at roughly USD 1,100 million in 2023, with further growth expected by 2034. Among the EU4 countries, Germany led the market in 2023 with an estimated value of about USD 100 million, while Spain recorded the smallest market size at approximately USD 40 million during the same year.

In 2023, the 7MM recorded approximately 6.2 million prevalent cases of Hidradenitis Suppurativa, with numbers expected to increase by 2034. The United States accounted for the highest number of diagnosed cases in the 7MM, totaling around 877,600 in 2023. Overall, the estimated total prevalent cases in the US were about 3 million in 2023, with further growth projected throughout the 2020–2034 study period.

Across all countries, the 30–39 age group constituted the largest share of Hidradenitis Suppurativa cases, making up nearly 25% of the total prevalent population. In contrast, the 0–17 age group had the fewest cases, representing about 2% of the total.

DelveInsight’s report “Hidradenitis Suppurativa Market Insights, Epidemiology, and Market Forecast-2034,” provides a comprehensive analysis of the Hidradenitis Suppurativa landscape. The report delivers detailed insights into the disease, including historical and projected epidemiology, helping stakeholders understand the prevalence, incidence, and patient demographics across key regions.

Additionally, it examines Hidradenitis Suppurativa market dynamics, offering a thorough assessment of current and emerging market trends, treatment patterns, and therapeutic developments. The analysis spans major markets, including the United States, EU4 (Germany, Spain, Italy, France, and the United Kingdom), and Japan, equipping decision-makers with actionable intelligence for strategic planning, investment, and research initiatives.

To Know in detail about the Hidradenitis Suppurativa market outlook, drug uptake, treatment scenario and epidemiology trends, Click here; Hidradenitis Suppurativa Market Forecast

Some of the key facts of the Hidradenitis Suppurativa Market Report: 

• Until 2023, HUMIRA held a significant market share in the treatment of hidradenitis suppurativa (HS) in the US. However, in October 2023, the US FDA approved COSENTYX for the management of moderate to severe HS in adults. COSENTYX stands as the sole FDA-approved fully human biologic that directly targets interleukin-17A (IL-17A), a cytokine implicated in the inflammation associated with Hidradenitis Suppurativa.
• Key Hidradenitis Suppurativa Companies: AbbVie, Novartis, UCB Biopharma, Eli Lilly, Institut Pasteur, UCB Biopharma SRL, MoonLake Immunotherapeutics, ACELYRIN Inc., Novartis, Phoenicis Therapeutics, Eli Lilly and Company, Beth Israel Deaconess Medical Center, Novartis, Sanofi, Boehringer Ingelheim, Incyte Corporation, and others
• Key Hidradenitis Suppurativa Therapies: HUMIRA, COSENTYX (secukinumab), BIMZELX (bimekizumab), Eltrekibart (LY3041658), ROCEPHIN, Bimekizumab, Sonelokimab, Izokibep, CFZ533, PTM-001, Eltrekibart, Upadacitinib, Deucravacitinib, secukinumab, SAR442970, Spesolimab, SAR444656, Lutikizumab, Povorcitinib, and others
• The Hidradenitis Suppurativa market is expected to surge due to the disease's increasing prevalence and awareness during the forecast period. Furthermore, launching various multiple-stage Hidradenitis Suppurativa pipeline products will significantly revolutionize the Hidradenitis Suppurativa market dynamics.

Hidradenitis Suppurativa Overview

Hidradenitis Suppurativa is a chronic, inflammatory skin disease characterized by painful lumps, abscesses, and tunnels (sinus tracts) that typically form in areas where skin rubs together, such as the underarms, groin, buttocks, and breasts. It occurs due to inflammation of hair follicles and can lead to scarring over time. HS is long-lasting, often progressive, and requires ongoing medical management to control symptoms and prevent flare-ups.
 
Get a Free sample for the Hidradenitis Suppurativa Market Forecast, Size & Share Analysis Report:

https://www.delveinsight.com/report-store/hidradenitis-suppurativa-market

Key Factors Driving The Hidradenitis Suppurativa Market:

• Rising Disease Prevalence and Underdiagnosis Awareness: Growing recognition of Hidradenitis Suppurativa as a chronic, painful inflammatory disorder is leading to higher diagnosis rates and increased demand for effective treatments.
• Advancements in Biologic and Targeted Therapies: Introduction of novel biologics and immunomodulators targeting inflammatory pathways is expanding the therapeutic landscape and driving market growth.
• Increasing Research Funding and Robust Clinical Pipeline: Active R&D efforts investigating next-generation biologics, small molecules, and combination therapies are fueling future market potential.
• Greater Focus on Quality-of-Life Improvements: The significant physical and psychological burden associated with HS is accelerating the adoption of advanced therapies to improve patient outcomes.
• Improved Healthcare Access and Reimbursement Support: Expanded insurance coverage for biologics and enhanced dermatology care infrastructure are improving treatment accessibility, contributing to market expansion.

Hidradenitis Suppurativa Epidemiology

The Hidradenitis Suppurativa epidemiology section provides insights into the historical, current, and forecasted epidemiology trends in the seven major countries (7MM) from 2020 to 2034. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. The epidemiology section also provides a detailed analysis of the diagnosed patient pool and future trends.

Hidradenitis Suppurativa Epidemiology Segmentation:

The Hidradenitis Suppurativa market report proffers epidemiological analysis for the study period 2020–2034 in the 7MM segmented into:

• Total Prevalent Cases of Hidradenitis Suppurativa in the 7MM
• Total Diagnosed Prevalent cases of Hidradenitis Suppurativa in the 7MM
• Gender-specific cases of Hidradenitis Suppurativa in the 7MM
• Age-specific cases of Hidradenitis Suppurativa in the 7MM
• Stage-specific cases of Hidradenitis Suppurativa in the 7MM
• Treated Prevalent cases of Hidradenitis Suppurativa in the 7MM

Download the report to understand which factors are driving Hidradenitis Suppurativa epidemiology trends @ Hidradenitis Suppurativa Epidemiology Forecast

Recent Developments In The Hidradenitis Suppurativa Treatment Landscape:

• In November 2025, Incyte broadened its support for initiatives addressing unmet needs to now include patients with hidradenitis suppurativa (HS), strengthening its engagement with the community as it prepares for regulatory submissions in this indication. The company introduced its Incyte Ingenuity Awards program in 2020 to fund projects aimed at helping underserved patient groups, beginning with graft-versus-host disease and vitiligo. By October 2024, Incyte had granted 13 awards to advocacy groups and healthcare organizations focused on improving care and quality of life for individuals affected by these conditions.
• In October 2025, Celltrion announced that the US Food and Drug Administration (FDA) has approved expanded indications for adalimumab-aaty (Yuflyma) and its unbranded counterpart to include the treatment of hidradenitis suppurativa (HS) in adolescents aged 12 years and older, as well as uveitis (UV) in pediatric patients aged 2 years and above.
• In May 2025, Ura Bio initiated the randomized Phase II TibuSHIELD trial to evaluate tibulizumab in adults with moderate to severe hidradenitis suppurativa (HS), also known as acne inversa. This double-blind, placebo-controlled, global study plans to enroll approximately 180 participants with HS across Canada, Europe, and the US.
• In March 2025, Incyte (Nasdaq: INCY) has reported promising topline results from its pivotal Phase 3 STOP-HS clinical program, which evaluated the safety and efficacy of povorcitinib (INCB054707) an oral small-molecule JAK1 inhibitor in adults aged 18 and above with moderate to severe hidradenitis suppurativa (HS). Both the STOP-HS1 and STOP-HS2 studies met their primary endpoints for the two tested doses (45 mg and 75 mg).
• In March 2025, UCB, a global biopharmaceutical company, has released two-year data from the BE HEARD^ trials assessing BIMZELX® (bimekizumab-bkzx) for treating moderate-to-severe hidradenitis suppurativa (HS). BIMZELX is the first and only approved therapy that specifically targets both interleukin 17A (IL-17A) and interleukin 17F (IL-17F). The findings highlight the drug’s continued effectiveness in delivering lasting symptom relief and consistent disease management, with promising potential to reduce the risk of long-term structural damage caused by draining tunnels (DTs).
• In September 2024, UCB, a global biopharmaceutical company, has presented two-year data from its Phase 3 BE HEARD I and BE HEARD II studies, along with their open-label extension, assessing the efficacy and safety of BIMZELX® (bimekizumab-bkzx) a dual interleukin (IL)-17A and IL-17F inhibitor—in adults with moderate-to-severe hidradenitis suppurativa (HS).
• In August 2024, ACELYRIN announced its decision to complete ongoing trials of Izokibep while halting new investments in hidradenitis suppurativa and psoriatic arthritis.
• In June 2024, The UK's Medicines and Healthcare products Regulatory Agency (MHRA) has approved UCB’s BIMZELX (bimekizumab) for the treatment of adults with active moderate-to-severe hidradenitis suppurativa.
• In May 2024, MoonLake Immunotherapeutics announced that the first patients have been screened at a U.S. trial site as part of its global Phase III VELA clinical program, which is evaluating sonelokimab, an investigational Nanobody for moderate-to-severe hidradenitis suppurativa
• In April 2024, the FDA accepted for review the supplemental Biologics License Application (sBLA) for BIMZELX for the treatment of adults with moderate-to-severe hidradenitis suppurativa. In addition, a second sBLA for the BIMZELX 2mL device presentations has also been accepted. Even after delivering promising data for BIMZELX hasn’t yet been approved in the US  for hidradenitis suppurativa.

Hidradenitis Suppurativa Drugs Uptake and Pipeline Development Activities

The drugs uptake section focuses on the rate of uptake of the potential drugs recently launched in the Hidradenitis Suppurativa market or expected to get launched during the study period. The analysis covers Hidradenitis Suppurativa market uptake by drugs, patient uptake by therapies, and sales of each drug.

Moreover, the therapeutics assessment section helps understand the drugs with the most rapid uptake and the reasons behind the maximal use of the drugs. Additionally, it compares the drugs based on market share.

The report also covers the Hidradenitis Suppurativa Pipeline Development Activities. It provides valuable insights about different therapeutic candidates in various stages and the key companies involved in developing targeted therapeutics. It also analyzes recent developments such as collaborations, acquisitions, mergers, licensing patent details, and other information for emerging therapies.

Hidradenitis Suppurativa Therapies and Key Companies

• HUMIRA: AbbVie
• COSENTYX (secukinumab): Novartis Pharmaceuticals
• BIMZELX (bimekizumab): UCB Biopharma
• Eltrekibart (LY3041658): Eli Lilly
• ROCEPHIN: Institut Pasteur
• Bimekizumab: UCB Biopharma SRL
• Sonelokimab: MoonLake Immunotherapeutics
• Izokibep: ACELYRIN Inc.
• CFZ533: Novartis
• PTM-001: Phoenicis Therapeutics
• Eltrekibart: Eli Lilly and Company
• Upadacitinib: AbbVie
• Deucravacitinib: Beth Israel Deaconess Medical Center
• secukinumab: Novartis
• SAR442970: Sanofi
• Spesolimab: Boehringer Ingelheim
• SAR444656: Sanofi
• Lutikizumab: AbbVie
• Povorcitinib: Incyte Corporation

Discover more about therapies set to grab major Hidradenitis Suppurativa market share @ Hidradenitis Suppurativa Treatment Landscape

Hidradenitis Suppurativa Market Drivers

• Rising prevalence and increased diagnosis of HS due to greater awareness of the chronic inflammatory condition.
• Advancements in biologics and targeted therapies improving treatment efficacy and patient outcomes.
• Growing research activity and strong clinical pipeline for novel therapies supporting market expansion.
• Focus on improving patient quality of life, driving demand for effective long-term treatment options.
• Expanded healthcare access and reimbursement policies facilitating adoption of advanced therapies.

Hidradenitis Suppurativa Market Barriers

• Limited curative treatment options; current therapies primarily manage symptoms and flare-ups.
• High recurrence rates leading to repeated interventions, increasing patient burden and treatment costs.
• Delayed diagnosis in certain regions due to lack of awareness or specialist access.
• Side effects and safety concerns associated with existing biologic and systemic therapies.
• Relatively small patient population in some regions limiting commercial incentives for major pharmaceutical investments.

Scope of the Hidradenitis Suppurativa Market Report

• Study Period: 2020–2034
• Coverage: 7MM [The United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan]
• Key Hidradenitis Suppurativa Companies: AbbVie, Novartis, UCB Biopharma, Eli Lilly, Institut Pasteur, UCB Biopharma SRL, MoonLake Immunotherapeutics, ACELYRIN Inc., Novartis, Phoenicis Therapeutics, Eli Lilly and Company, Beth Israel Deaconess Medical Center, Novartis, Sanofi, Boehringer Ingelheim, Incyte Corporation, and others
• Key Hidradenitis Suppurativa Therapies: HUMIRA, COSENTYX (secukinumab), BIMZELX (bimekizumab), Eltrekibart (LY3041658), ROCEPHIN, Bimekizumab, Sonelokimab, Izokibep, CFZ533, PTM-001, Eltrekibart, Upadacitinib, Deucravacitinib, secukinumab, SAR442970, Spesolimab, SAR444656, Lutikizumab, Povorcitinib, and others
• Hidradenitis Suppurativa Therapeutic Assessment: Hidradenitis Suppurativa current marketed and Hidradenitis Suppurativa emerging therapies
• Hidradenitis Suppurativa Market Dynamics: Hidradenitis Suppurativa market drivers and Hidradenitis Suppurativa market barriers
• Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter’s five forces, BCG Matrix, Market entry strategies
• Hidradenitis Suppurativa Unmet Needs, KOL’s views, Analyst’s views, Hidradenitis Suppurativa Market Access and Reimbursement 

To know more about Hidradenitis Suppurativa companies working in the treatment market, visit @ Hidradenitis Suppurativa Clinical Trials and Therapeutic Assessment